ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma

Blood Advances - Tập 4 - Trang 2548-2555 - 2020
Steven I. Park1, Thomas C. Shea2, Oludamilola Olajide3, Nishitha M. Reddy4, Lihua E. Budde5, Nilanjan Ghosh1, Allison M. Deal6, Jeanne F. Noe2, Stephen M. Ansell7
1Levine Cancer Institute, Charlotte, NC
2University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3University of North Carolina REX Healthcare, Raleigh, NC
4Department of Medicine, Vanderbilt University, Nashville, TN
5City of Hope, Duarte, CA
6Biostatistics and Data Management, University of North Carolina, Chapel Hill, NC
7Mayo Clinic, Rochester, MN

Tóm tắt

Abstract

Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to reduce the use of radiation therapy (RT) as well as conventional chemotherapy drugs while improving upon current standard-of-care survival outcomes. In this phase 2 multicenter study, patients with non-bulky limited-stage HL received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by brentuximab vedotin (BV) consolidation. Forty-one patients were enrolled, and patient characteristics included median age of 29 years (range, 19 to 67 years), 58% were female, 45% had unfavorable disease, and 98% had stage II disease. Based on positron emission tomography (PET)–based risk stratification, patients received 2 to 6 cycles of ABVD followed by 6 cycles of BV. After ABVD followed by BV, 95% of evaluable patients (37 out of 39; 95% confidence interval [CI], 83%-99%) achieved PET-negative status. In the intent-to-treat patient population, the estimated 3-year progression-free survival (PFS) rate was 92%, and the overall survival (OS) rate was 97%, with a median follow-up of 47 months. All 37 patients who achieved negative PET status after BV consolidation effectively avoided RT and remain in remission with estimated 3-year PFS and OS rates of 100%. In conclusion, BV demonstrates encouraging clinical activity when it follows ABVD therapy in limited-stage HL. Early incorporation of BV may reduce the use of RT as well as conventional chemotherapy drugs while achieving favorable survival outcomes in risk-stratified patients with non-bulky limited-stage HL. This trial was registered at www.clinicaltrials.gov as #NCT01578967.


Tài liệu tham khảo

Thomas, 2002, Epidemiology and etiology of Hodgkin’s lymphoma, Ann Oncol, 13, 147, 10.1093/annonc/mdf652 Ng, 2011, Long-term complications of lymphoma and its treatment, J Clin Oncol, 29, 1885, 10.1200/JCO.2010.32.8427 Radford, 2015, Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma, N Engl J Med, 372, 1598, 10.1056/NEJMoa1408648 Schaapveld, 2015, Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma, N Engl J Med, 373, 2499, 10.1056/NEJMoa1505949 Maraldo, 2015, Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials, Lancet Haematol, 2, e492, 10.1016/S2352-3026(15)00153-2 Hapgood, 2016, Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia, J Clin Oncol, 34, 2493, 10.1200/JCO.2015.65.4194 Gopal, 2015, Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, Blood, 125, 1236, 10.1182/blood-2014-08-595801 Moskowitz, 2015, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 385, 1853, 10.1016/S0140-6736(15)60165-9 Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Barrington, 2014, Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J Clin Oncol, 32, 3048, 10.1200/JCO.2013.53.5229 Engert, 2010, Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma, N Engl J Med, 363, 640, 10.1056/NEJMoa1000067 Ansell, 2018, Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management, Am J Hematol, 93, 704, 10.1002/ajh.25071 Hoppe, 2017, Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 15, 608, 10.6004/jnccn.2017.0064 van Eggermond, 2014, Risk of multiple primary malignancies following treatment of Hodgkin lymphoma, Blood, 124, 319, 10.1182/blood-2013-10-532184 Yeh, 2012, Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks, Blood, 120, 2195, 10.1182/blood-2012-02-409821 Barbaro, 2011, Reduced incidence of second solid tumors in survivors of childhood Hodgkin’s lymphoma treated without radiation therapy, Ann Oncol, 22, 2569, 10.1093/annonc/mdr013 Swerdlow, 2011, Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study, J Clin Oncol, 29, 4096, 10.1200/JCO.2011.34.8268 Swerdlow, 2000, Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment, J Clin Oncol, 18, 498, 10.1200/JCO.2000.18.3.498 Lagerlöf, 2020, No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy, Br J Haematol, 188, 685, 10.1111/bjh.16232 Specht, 2014, Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG), Int J Radiat Oncol Biol Phys, 89, 854, 10.1016/j.ijrobp.2013.05.005 Aleman, 2007, Late cardiotoxicity after treatment for Hodgkin lymphoma, Blood, 109, 1878, 10.1182/blood-2006-07-034405 van Nimwegen, 2017, Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines, Blood, 129, 2257, 10.1182/blood-2016-09-740332 Howe, 2003, Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma, Bone Marrow Transplant, 32, 317, 10.1038/sj.bmt.1704124 Bessell, 2012, Long-term survival after treatment for Hodgkin’s disease (1973-2002): improved survival with successive 10-year cohorts, Br J Cancer, 107, 531, 10.1038/bjc.2012.228 Ng, 2014, Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects, Blood, 124, 3373, 10.1182/blood-2014-05-579193 Straus, 2018, CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET, Blood, 132, 1013, 10.1182/blood-2018-01-827246 André, 2017, Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial, J Clin Oncol, 35, 1786, 10.1200/JCO.2016.68.6394 Fuchs, 2019, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, J Clin Oncol, 37, 2835, 10.1200/JCO.19.00964 Kumar, 2016, Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma, Blood, 128, 1458, 10.1182/blood-2016-03-703470 Abramson, 2019, Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma, Blood, 134, 606, 10.1182/blood.2019001272 Younes, 2013, Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study, Lancet Oncol, 14, 1348, 10.1016/S1470-2045(13)70501-1 Straus, 2020, Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study, Blood, 135, 735, 10.1182/blood.2019003127 Fanale, 2015, Treatment strategies to optimize outcomes with brentuximab vedotin: Management of common and rare toxicities, J Target Ther Cancer, 4, 36 Gandhi, 2014, Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event, Blood, 123, 2895, 10.1182/blood-2014-03-561878 Parsons, 2018, Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes, Br J Haematol, 182, 212, 10.1111/bjh.15255 Kumar, 2016, Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes, Haematologica, 101, 1237, 10.3324/haematol.2016.141846 Illidge, 2020, Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma, Blood Adv, 4, 203, 10.1182/bloodadvances.2019001023
Thông tin
Thông tin xuất bản

Blood Advances

Tập 4

2548-2555

Thông tin tác giả